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Abstract
Background: Pituitary tumor transforming gene (PTTG) is a novel oncogene that is expressed
abundantly in most tumors. Overexpression of PTTG induces cellular transformation and promotes
tumor formation in nude mice. PTTG has been implicated in various cellular processes including
sister chromatid separation during cell division as well as induction of apoptosis through p53-
dependent and p53-independent mechanisms. The relationship between PTTG and p53 remains
unclear, however.
Results: Here we report the effects of overexpression of PTTG on the expression and function of
p53. Our results indicate that overexpression of PTTG regulates the expression of the p53 gene at
both the transcriptional and translational levels and that this ability of PTTG  to activate the
expression of p53 gene is dependent upon the p53 status of the cell. Deletion analysis of the p53
gene promoter revealed that only a small region of the p53 gene promoter is required for its
activation by PTTG and further indicated that the activation of p53 gene by PTTG is an indirect effect
that is mediated through the regulation of the expression of c-myc, which then interacts with the
p53 gene promoter. Our results also indicate that overexpression of PTTG stimulates expression
of the Bax gene, one of the known downstream targets of p53, and induces apoptosis in a human
embryonic kidney cell line (HEK293). This stimulation of bax expression by PTTG is indirect and is
mediated through modulation of p53 gene expression.
Conclusions: Overexpression of PTTG activates the expression of p53 and modulates its function,
with this action of PTTG being mediated through the regulation of c-myc expression. PTTG also up-
regulates the activity of the bax promoter and increases the expression of bax through modulation
of p53 expression.
Background
The pituitary tumor transforming gene (PTTG), a securin,
was cloned initially from a rat pituitary tumor [1]. Subse-
quently, we and others cloned the human PTTG gene [2,3]
and characterized its function. PTTG protein is expressed
at higher than normal levels in several tumors, including
those of the pituitary [4], thyroid [5], colon [6], ovary [7],
testis [7] and breast [8], as well as in hematopoietic neo-
plasms [9]. In some tumors, including those of the thy-
roid [10], pituitary [11], esophagus [12] and colorectum
[6], high levels of expression of PTTG correlate with tumor
invasiveness and, more recently, PTTG has been identified
as a key "signature gene", with high expression predicting
metastasis in multiple tumor types [13]. Overexpression
of  PTTG  enhances cell proliferation, induces cellular
transformation, and promotes tumor formation in nude
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mice [2,3]. The involvement of PTTG in several cellular
functions, such as mitosis [14,15], cell cycle progression
[16], DNA repair [17] and secretion and expression of
basic fibroblast growth factor (bFGF) [18] and vascular
endothelial growth factor (VEGF) [19] has been reported.
Structural homology suggested that PTTG may be a mam-
malian securin and this has been confirmed by its involve-
ment in regulating sister chromatid separation during
mitosis [16]. The involvement of PTTG in cell signaling
via the MAP kinase cascade [20] and its interaction with
the  c-myc  promoter suggest its involvement in cellular
transformation [21].
There is now considerable evidence supporting the con-
cept that PTTG  can regulate apoptosis in both a p53-
dependent and a p53-independent manner [22]. In their
studies, Yu et al. [22] have shown that overexpression of
PTTG results in the induction of apoptosis of cells that are
p53 deficient (osteosarcoma MG-63 cells), as well as cells
that express functional p53 (breast tumor MCF-7 cells),
with overexpression of both PTTG and p53 resulting in an
increase in apoptosis of MCF-7 cells but not MG-63 cells.
However, overexpression of E6, which targets p53 for deg-
radation, eliminated p53  in MCF-7 cells but did not
inhibit apoptosis on overexpression of PTTG. Analysis of
the molecular basis for the interaction between PTTG and
p53 by these investigators [22] showed that overexpres-
sion of PTTG in MCF-7 cells resulted in an increase in
translocation of p53 protein to the nucleus. Subsequently,
Bernal et al. [23] using phage-display screening identified
an interaction of the p53 and PTTG proteins in vitro and in
vivo. These investigators found that this interaction of p53
with PTTG  inhibited the transcriptional activity of p53
and its ability to induce cell death in MCF-7 cells. These
investigators did not find activation of p53 expression on
overexpression of PTTG  in the lung tumor cell line,
H1299. In these cells, overexpression of both PTTG and
p53 resulted in down regulation of p53-induced apoptosis
together with down regulation of the p53-induced expres-
sion of downstream signaling genes, including Bax, SFN,
and CDKN1A suggesting that, in these cells, PTTG inhibits
the function of p53 rather than its expression.
Our previous analysis of the PTTG  promoter revealed
tumor-specific activation of the promoter in various cell
lines and indicated that Sp1 and NF-Y binding sites within
the PTTG  promoter are involved in its activation [24].
Zhou et al. [25] recently confirmed that Sp1 and NF-Y are
involved in the expression of PTTG and that these binding
sites play an important role in the regulation of the expres-
sion of PTTG by p53. We therefore undertook an analysis
of the mechanisms by which PTTG regulates p53 expres-
sion and function. Here, we report that PTTG regulates
p53 expression and function by modulating the activity of
the  p53  promoter indirectly through regulation of the
expression of c-myc, which binds directly to the p53 pro-
moter sequence.
Results
PTTG upregulates expression of p53 in HEK293 and 
MCF-7 cells
To determine the relationship between PTTG and p53, we
first determined the effect of overexpression of PTTG on
p53 expression. For this purpose, we used three different
cell lines. Two of these HEK293, which is a human embry-
onic kidney cell line, and MCF-7, which is a human breast
cancer cell line, express wild-type p53, and one, PC3,
which is a human prostate cancer cell line expresses a
mutant form of p53. As shown in Figure 1A, western blot
analysis of the lysates prepared from HEK293 and MCF-7
cells that had been transiently transfected with pcDNA-
PTTG revealed a significant increase in expression of both
PTTG and p53 proteins compared to cells transfected with
vector only. Consistent with the data reported by Rokhlin
et al. [26], we did not detect p53 protein on Western blot-
ting of lysates prepared from PC-3 cells that had been
transfected with pcDNA3.1-PTTG  or pcDNA3.1 vector
only. To confirm that overexpression of PTTG activates
expression of p53, we performed double immunohisto-
chemical analysis of HEK293 cells transfected with
pcDNA3.1-PTTG. As shown in Figure 1B, the cells that
exhibited staining of the PTTG protein and showed high
levels of expression of PTTG also exhibited intense stain-
ing of the p53 protein. Staining of PTTG  and p53 was
either absent or very weak in HEK293 cells that had been
transfected with pcDNA3.1 vector alone. These results
suggested that PTTG upregulates the expression of p53.
The up-regulation of expression of p53 by PTTG could be
attributed to an alteration in the stability of the mRNA, an
alteration in the efficiency of translation, or altered gene
transcription. To determine whether the change in expres-
sion of p53 is due to an alteration in the transcription of
the p53 gene, we analyzed the p53 gene promoter activity
and its regulation by PTTG. As shown in Fig. 2, transient
transfection of cells with pcDNA3.1-PTTG resulted in a 3-
fold higher level of p53 promoter activity in MCF7 cells, a
2.3-fold higher level in PC3 cells, and a 1.6-fold higher
level in HEK293 cells as compared to the levels of pro-
moter activity in the same cell lines on transfection with
pCDNA3.1vector only. Taken together, these results
clearly demonstrate that up-regulation of p53 expression
is, at least in part, due to up-regulation of transcription of
the p53 gene by the PTTG protein.
Up-regulation of p53 promoter activity by PTTG is 
mediated by regulation of expression of the c-myc gene
To map the region of the p53 promoter sequence that is
required for activation by PTTG, we performed 5' and 3'-Molecular Cancer 2004, 3:18 http://www.molecular-cancer.com/content/3/1/18
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deletion analysis of the p53 gene promoter sequence and
identified a small segment of 84 base pairs (from nucle-
otide -172 to -89) located near the transcription start site
of p53 gene that is responsible for activation (Fig. 3). This
region has been demonstrated previously to be important
for p53 promoter activity [27]. DNA foot printing and gel
shift assays using the 84 bp p53 promoter sequence and
purified PTTG recombinant protein did not indicate direct
binding of the PTTG  protein to the p53  promoter
sequence (data not shown), suggesting that the PTTG pro-
tein does not bind the p53 promoter sequence directly.
Sequence analysis of the 84 bp activation region of the p53
promoter revealed binding sites for the nuclear factors,
NFκB and c-myc/max  heterodimers. The importance of
these transcription factors in the regulation of p53 pro-
moter activity has been demonstrated previously [28]. Pei
[22] had demonstrated binding of PTTG to the c-myc pro-
Expression of PTTG and p53 proteins in MCF7, HEK293 and PC3 cells transfected with either pcDNA 3.1 (Lane 1) or  pcDNA3.1-PTTG cDNA (lane 2) Figure 1
Expression of PTTG and p53 proteins in MCF7, HEK293 and PC3 cells transfected with either pcDNA 3.1 (Lane 1) or 
pcDNA3.1-PTTG cDNA (lane 2). A: Expression of PTTG and p53 proteins was analyzed by western blot analysis using a PTTG- 
or p53-specific antibody as described in Methods. A β-Actin antibody was used as a control to determine the variation in pro-
tein concentration and loading. B: Double immunocytochemical analysis of HEK293 cells for the co-expression of PTTG and 
p53 proteins. HEK293 cells were transiently transfected with PTTG cDNA. After 48 hours of transfection, the cells were sub-
jected to immunofluorescence analysis using PTTG-specific antiserum and a p53 monoclonal antibody. Panel A: Cells trans-
fected with pcDNA3.1 vector. Panel B: Cells transfected with pcDNA3.1-PTTG cDNA. 1, pre-immune serum; 2, PTTG 
antiserum; 3, p53-specific monoclonal antibody, and 4, overlay of 2 and 3 showing co-expression of PTTG and p53 proteins.Molecular Cancer 2004, 3:18 http://www.molecular-cancer.com/content/3/1/18
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moter sequence near its transcription start site, and
stimulation of c-myc transcription by PTTG. As PTTG does
not exhibit direct binding to the p53 promoter sequence,
we hypothesized that PTTG may modulate p53 promoter
activity indirectly through its interaction with c-myc/max.
To test our hypothesis, we investigated the role of c-myc in
the regulation of p53  promoter activity. We first con-
firmed the effect of overexpression of PTTG  on  c-myc
expression in HEK293 cells (data not shown). We then
determined the effects of PTTG on binding of c-myc to the
p53 promoter sequence by creating a mutation within the
c-myc-binding sequence, CATGTG, that is known to
abrogate binding of c-myc/max  to the p53  promoter
sequence and result in a loss of c-myc  effects [28]. As
shown in Fig. 4, mutation of the c-myc/max CATGTG bind-
ing sequence to CTTGGA resulted in a complete loss of the
effects of PTTG on p53 promoter activity in both HEK293
and PC-3 cell lines, suggesting that PTTG regulates p53
promoter activity by modulating the expression of the c-
myc gene, which in turn binds to the c-myc/max sequence
of the p53 promoter.
To further characterize the effect of PTTG on the interac-
tion of c-myc/max with the p53 promoter sequence, we
performed gel shift analysis using a γ-[32P]-labeled probe
derived from the p53  gene promoter sequence (from
nucleotide -172 to -89) containing either the wild-type
(CATCTG) or mutated (CTTGGA) c-myc/max  binding
sequence. As shown in Fig. 5, gel mobility shift assays of
nuclear extracts prepared from HEK293 cells transfected
with pcDNA3.1-PTTG indicated an enhanced binding of
the c-myc protein to the c-myc/max sequence (Fig. 5A and
5B, Lane 2) compared to that observed in extracts
prepared from HEK293 cells transfected with pcDNA3.1
vector only (Fig. 5A and 5B, Lane 1). This binding of c-myc
to the c-myc/max sequence was specific, since the inclusion
of a 20-fold molar excess of unlabeled specific sequence in
the reaction mixture resulted in almost complete abroga-
tion of this binding (Fig. 5A, Lane 3), and pre-incubation
of the nuclear extract with a c-myc-specific antibody
directed against the N-terminal region of the c-myc protein
resulted in a supershift (Fig. 5B, Lane 3). Furthermore, on
use of the mutated c-myc sequence (p53/-172/-89-∆-c-myc)
as the probe in the gel shift assays, neither binding of c-
myc (Fig. 5B, Lane 5) nor supershift of the binding com-
plex (Fig. 5B, Lane 6) was observed. It is known that the c-
myc protein is highly unstable and has only a short half-
life but that it can be stabilized by the binding of its part-
ner,  max, at its C-terminal [29]. This c-myc/max  het-
erodimer binds to the c-myc/max target sequence on the
p53 promoter and mediates various effects [30]. To con-
firm whether c-myc binds to the c-myc/max sequence alone
or in association with max, we used antibodies directed
against the C-terminal of the c-myc protein in the super-
shift assays. Inclusion of these antibodies negated the
supershift of the DNA-protein complex (Fig. 5B, Lane 4),
indicating that in these circumstances the C-terminal of c-
myc is not accessible and is probably associated with max.
To further validate the role of c-myc in the induction of
p53 promoter activity on PTTG overexpression, we uti-
lized a dominant-negative chimeric protein (myc DN), a
myc-max fusion containing the DNA-binding domain of
max fused to a transactivation-deficient c-myc [31]. It has
been shown previously that when myc DN is overex-
pressed, it can bind to E boxes with high affinity, but that
it cannot induce transcription and antagonizes c-myc func-
tion in a dominant-negative way [31]. As shown in Fig. 6,
co-transfection of Myc DN with the p53-promoter con-
struct resulted in a complete loss of activation of the p53
promoter (Fig. 6A) and the induction of its expression by
PTTG (Fig. 6B). These effects of Myc DN appear to be spe-
cific, since no changes in p53  promoter activity or its
expression were observed in HEK293 cells when co-trans-
fected with Myc DN and the pcDNA3.1 vector (Fig. 6A
and 6B). In addition, expression of Myc DN in HEK293
cells did not block the expression of the PTTG protein
Overexpression of PTTG activates p53 gene promoter and  expression Figure 2
Overexpression of PTTG activates p53 gene promoter and 
expression. MCF7, PC3 and HEK293 cells were co-trans-
fected with the p53 gene promoter and PTTG expression 
vectors. The fold increases in luciferase activity on transfec-
tion of cells with PTTG expression vector (solid bars) com-
pared to cells transfected with vector only (open bars) is 
shown. Transfections were performed in duplicate and the 
results are expressed as mean ± S.E.M of four independent 
experiments (*, p < 0.05 by Student's t-test).Molecular Cancer 2004, 3:18 http://www.molecular-cancer.com/content/3/1/18
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(Fig. 6B), suggesting that PTTG protein up-regulates the
transcription and expression of the p53  gene and this
action of PTTG is achieved through modulation of c-myc
expression and function.
PTTG activates bax gene expression by inducing p53 
expression
To assess whether overexpression of PTTG modulates the
transactivation properties of p53, we determined the effect
of PTTG on bax promoter activity, as bax is a known to be
a proapototic molecule that is induced by p53. The bax
gene is a pro-apoptotic member of the bcl-2 gene family
[32] and its regulation by p53 is well documented [33].
Co-transfection of MCF7 and HEK293 cells with
pcDNA3.1-PTTG  and the bax gene promoter showed a
dose-dependent stimulation of the bax promoter activity
in both HEK293 and MCF-7 cell lines (Fig. 7A). Western
blot analysis of lysates of HEK293 and MCF-7 cell lines
transfected with pcDNA3.1-PTTG revealed enhancement
of the levels of bax protein compared with the levels in
cells transfected with pCDNA3.1 vector only (Fig. 7B).
These results suggest that the PTTG protein up-regulates
bax  gene transcription and expression. It remains
unknown if this effect of PTTG  is direct or mediated
through p53 gene regulation; however, transfection of PC-
3 cells, which do not express functional p53, with
pcDNA3.1-PTTG  did not result in an increase in the
expression of bax (Fig. 7B). Taken together, these results
suggest a relationship between PTTG and p53 in the regu-
lation of p53 downstream signaling pathways by PTTG.
Overexpression of PTTG induces apoptosis
Finally, we determined the effect of PTTG overexpression
on apoptosis. Apoptotic cells were not detectable on
TUNEL staining of HEK293 cells that had been transiently
transfected with the pcDNA 3.1 vector alone (Fig. 8A). In
contrast, apoptotic cells were apparent on transient trans-
fection of the HEK293 cells with either PTTG or p53 cDNA
(Fig. 8A). Furthermore, flow cytometric analysis of
HEK293 transfected with PTTG or p53 cDNA indicated
that a greater number of cells in G1 phase in both PTTG-
transfected (12%) and p53-transfected (22.6%) cells than
in pcDNA 3.1-transfected cells (Fig. 8B), indicating that
Mapping of the PTTG interacting region in the p53 promoter sequence Figure 3
Mapping of the PTTG interacting region in the p53 promoter sequence. HEK293 cells (open bars) and PC3 cells (solid bars) 
were co-transfected with various 5' and 3' deleted constructs of p53 promoter and pcDNA3.1-PTTG. The sequence of the p53 
promoter construct (p53/-172/-89) containing the c-myc/max binding sequence is shown. The '*' indicates the position of c-myc/
max binding sequence. Transfections were performed in duplicate and the results are expressed as mean ± S.E.M of four inde-
pendent experiments (*, p < 0.05 by Student's t-test). Results are represented as the fold increase compared to control 
(pcDNA3.1)-transfected cells.Molecular Cancer 2004, 3:18 http://www.molecular-cancer.com/content/3/1/18
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PTTG and p53 cDNA induce cell cycle arrest at the G1
phase.
Discussion
The present study was focused on determining the mech-
anism(s) by which PTTG regulates the expression of p53.
For this purpose, we used three different cell lines:
HEK293 and MCF7, which express wild-type p53; and PC-
3, which expresses a mutant form of p53 that is degraded
rapidly. Overexpression of PTTG led to activation of p53
expression in the HEK293 and MCF-7 cell lines, but not
the control PC-3 cells (Fig. 1A). Immunohistochemical
analysis of the HEK293 cells that had been transfected
with pcDNA3.1-PTTG confirmed that overexpression of
PTTG protein resulted in high levels of expression of the
p53 protein (Fig. 1B). The activation of the expression of
the p53 protein by PTTG in MCF-7 cells is consistent with
the findings of Yu et al. [22] who reported an increase in
expression of p53 and its translocation into nucleus on
overexpression of PTTG in these cells. In their studies, Yu
et al. [22] did not find simultaneous accumulation of p53
and mdm2 in the nucleus, indicating that PTTG may not
use the ARF mechanism to induce p53 expression. It is
possible that PTTG may induce p53 nuclear accumulation
by inhibiting mdm2 expression through other
mechanisms [34]. It also is possible that enhancement of
the expression of p53 may lead to the activation of other
pathways, which could alter the expression of other genes
or the interaction of p53  with other proteins [35]. For
example, enhanced p53 may activate bax, an antagonist of
Bcl-2 [36], or enhance the synthesis of insulin-like growth
factor-I (IGF-I) receptor and one of its binding proteins,
IGF-BP3 [37].
The mechanisms by which PTTG up-regulates the expres-
sion of p53 may include enhancement of the stability of
mRNA, an improvement in translation efficiency, or
enhanced transcription of the gene. Our studies suggest
that the enhanced expression of the p53 gene is due, at
least in part, to an increase in p53 promoter activity. It has
Activation of the p53 promoter by PTTG is mediated through  the c-myc/max sequence Figure 4
Activation of the p53 promoter by PTTG is mediated through 
the c-myc/max sequence. HEK293 (open bars) and PC3 (solid 
bars) were co-transfected with the pcDNA3.1-PTTG and  
p53/-172/-89 (wild-type myc/max binding sequence) or the 
p53/-172/-89-∆-c-myc (mutated myc/max binding sequence) 
promoter construct. Transfections were performed in dupli-
cate and the results are expressed as mean ± S.E.M of four 
independent experiments (*, p < 0.05 by Student's t-test).
Electrophoretic mobility shift assays show the binding of c- myc protein to the c-myc/max sequence Figure 5
Electrophoretic mobility shift assays show the binding of c-
myc protein to the c-myc/max sequence. A: Nuclear extract 
prepared from HEK293 cells transfected either with 
pcDNA3.1 (lane 1) or pcDNA3.1-PTTG (lane 2) and [32P]-
labeled p53 gene promoter sequence carrying a normal c-
myc/max binding site. Addition of a 20-fold molar excess of 
specific unlabeled DNA resulted in almost complete disap-
pearance of the DNA-protein complex (lane 3). An arrow 
indicates the specific DNA-protein complex. B: Nuclear 
extracts prepared from HEK293 cells transfected either with 
pcDNA3.1 (lane 1) or pcDNA3.1-PTTG (lane 2) and [32P]-
labeled p53 promoter sequence carrying a normal c-myc/max 
binding site. Addition of antibody directed against the N-ter-
minal of c-myc resulted in a supershift (lane 3, indicated by an 
arrow) whereas no supershift was obtained when the [32P]-
labeled-D-172/-89 c-myc sequence was used as a probe (lane 
5). Addition of antibodies directed against the C-terminal of 
c-myc did not result in supershift (lanes 4 & 6) when either of 
the probes was used in the binding reaction indicating that C-
terminal of c-myc is not assessable. N.S indicates non-specific 
complex.Molecular Cancer 2004, 3:18 http://www.molecular-cancer.com/content/3/1/18
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been shown that the PTTG possesses transactivating [38]
and DNA binding properties [21]. We therefore expected
that PTTG might regulate p53 promoter activity by virtue
of its direct binding to the p53 gene promoter sequence;
however, our DNA foot printing and gel shift assays
showed no direct binding of PTTG protein to the p53 pro-
moter sequence, suggesting that PTTG modulates p53 pro-
moter activity through an indirect mechanism.
Subsequent 5' and 3' deletion analysis of the p53 gene
promoter identified the sequence between nucleotides -
172 to -89, which contains a c-myc/max binding sequence,
as being responsive to PTTG activation. In previous stud-
ies, Pei [21] demonstrated binding of PTTG protein to the
c-myc gene promoter sequence near its transcription start
site and its activation by PTTG. Therefore, it is possible
that the enhancement of expression of the p53 gene by
PTTG is a result of enhancement of the expression of c-
myc. The resulting c-myc would then interact with its part-
ner, max, to form a heterodimer that binds to the p53 pro-
moter and regulates its transcription. Binding of the c-myc
protein to this sequence was confirmed by gel mobility
shift and super shift assays, which revealed specific bind-
c-myc is essential for activation of p53 expression by PTTG Figure 6
c-myc is essential for activation of p53 expression by PTTG. A: Co-transfection of HEK293 cells with the c-myc dominant-nega-
tive (Myc DN) construct, p53 gene promoter and PTTG cDNA. Transfections were performed in duplicate and results are 
expressed as mean of two independent experiments. B: Western blot analysis of HEK293 cells transfected with either pcDNA 
3.1, the c-myc dominant-negative (Myc DN) and/or PTTG cDNA. Expression was detected using specific antibodies. β-Actin 
antibody was used as a control to determine the variation in protein concentration and loading.Molecular Cancer 2004, 3:18 http://www.molecular-cancer.com/content/3/1/18
Page 8 of 13
(page number not for citation purposes)
ing of the c-myc  protein to this sequence. Site-directed
mutagenesis of the c-myc/max sequence resulted in a com-
plete loss of binding of the c-myc protein and p53 pro-
moter activation by PTTG. The importance of c-myc  in
regulating expression of the p53 gene by PTTG is further
supported by the results generated using a c-myc domi-
nant-negative construct that abolished the induction of
p53 gene expression by PTTG. These results demonstrate
clearly that PTTG up-regulates the expression and tran-
scription of the p53 gene by modulating the expression of
the c-myc gene and its binding to the c-myc/max sequence
on the p53 promoter.
PTTG is an oncogene and has been shown to induce cel-
lular transformation in vitro and promote tumor forma-
tion in nude mice [2]. In an attempt to define the
mechanism by which PTTG contributes to tumorigenesis,
Bernal et al. [23] used phage display screening and deter-
mined that the p53 protein interacts with the PTTG pro-
tein both in vitro and in vivo leading to inhibition of the
transcriptional activity of p53 and its ability to induce cell
death. In contrast to our results, these investigators did
not find that PTTG altered the expression of p53. In their
studies, these investigators showed a very low or marginal
increase in the levels of PTTG protein on transfection with
PTTG cDNA. Therefore, the discrepancy between Bernal's
findings and ours may be attributable to the requirement
for a threshold amount of PTTG protein for induction of
p53 promoter activity. Zhou et al. [25] showed suppres-
sion of p53 expression in cells treated with the DNA-dam-
aging drugs doxorubicin and bleomycin. This drug-
induced suppression of PTTG was shown to be dependent
on the presence of functional p53. In their studies, these
investigators [25] showed direct suppression of PTTG
expression by p53 through its interaction with the NF-Y
transcription factor binding sequence of the PTTG pro-
moter, suggesting that the PTTG gene is a target of p53 and
may play a role in the p53-mediated cellular response to
DNA damage.
Overexpression of PTTG activates the expression of bax by upregulating p53 expression Figure 7
Overexpression of PTTG activates the expression of bax by upregulating p53 expression. A: MCF7 cells (open bars) and 
HEK293 cells (solid bars) were co-transfected with the bax promoter and increasing amounts of the pCDNA3.1-PTTG expres-
sion vector. Transfections were performed in duplicate and the results are expressed as the mean ± S.E.M of four independent 
experiments (*, p < 0.05 by Student's t-test). Results are represented as the fold increase compared to control. B: Western 
blot analysis of HEK293, MCF7 and PC3 cells transfected with PTTG for the expression of bax after 48 hours of transfection. β-
Actin antibody was used as a control to assess any variation in protein concentration and loading.Molecular Cancer 2004, 3:18 http://www.molecular-cancer.com/content/3/1/18
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Our results show that overexpression of PTTG activates
p53 expression, and that this action of PTTG is achieved
through the regulation of the expression of c-myc, which
in turn regulates the expression of the p53 gene, by its
direct binding to the c-myc/max sequence of the p53 pro-
moter. The importance of c-myc in the induction of the
expression of p53 by PTTG is further revealed by our stud-
ies using a c-myc dominant-negative construct (Fig 6A and
6B). These results are consistent with those of Kirch et al.
[28] and Levine [39] who also documented the
importance of c-myc for p53 expression and activation.
Furthermore, c-myc has been reported to promote apopto-
sis by destabilizing mitochondrial integrity in coopera-
tion with proapoptotic members of the BCL-2 family
including bax [40] and it is considered as an important
transcription factor [41]. Thus, its role in the induction of
p53 expression seems to be of physiologic importance in
the control of genomic stability in cells.
PTTG overexpression induces apoptosis Figure 8
PTTG overexpression induces apoptosis. A: HEK293 cells were transfected with pcDNA 3.1 vector (1), PTTG cDNA (2), or 
p53 cDNA (3) for 48 hours before the TUNEL assay. B: Transfected HEK293 cells also were analyzed for apoptosis by flow 
cytometry. Plots show an accumulation of G1 cells upon transfection with PTTG and both an induction of sub-G1 and loss of 
G2 cells upon p53 transfection. Data are representative of two independent experiments, performed in triplicate.Molecular Cancer 2004, 3:18 http://www.molecular-cancer.com/content/3/1/18
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To assess the significance of the activation of p53 by PTTG
with respect to the function of p53  in apoptosis and
activation of downstream signaling genes, we analyzed
apoptosis using TUNEL staining as well as the activation
of the bax promoter. The bax gene encodes a pro-apoptotic
member of BCL-2 gene family [32] and its regulation by
p53 is well documented [33]. Our results indicate that
overexpression of PTTG  induces  bax  promoter activity
(Fig. 7A). PTTG overexpression also induces apoptosis in
HEK293 cells (Fig. 8). These results are in agreement with
the earlier reports of PTTG overexpression inducing apop-
tosis by p53-dependent and independent mechanisms
[22]. It would seem that when both of these apoptotic
pathways fail, PTTG can support the survival of aneuploid
cells, thereby supporting tumor growth.
Conclusions
Our studies reveal that the PTTG protein can up-regulate
expression of p53 in cells dependent on their p53 status.
This stimulatory effect of PTTG is indirect and is mediated
through c-myc. PTTG also up-regulates the activity of the
bax promoter and increases the expression of bax through
modulation of p53 expression.
Methods
Construction of reporter plasmids
We cloned the human p53 gene promoter from nucle-
otides -531 to -3 (p53/-531/-3) into the promoterless and
enhancerless basic pGL3 vector (Promega, Madison, Wis-
consin). Briefly, the p53 gene promoter sequence (from
nucleotide -531 to -3) was amplified using human
genomic DNA (Promega, Madison, Wisconsin) as a tem-
plate and selected sense/antisense primers (sense; 5'-
TAGAGCTCGGGAGAAAACGTTACGGT-3' ; antisense; 5'-
TACTCGAGAATCCAGGGA AGCGT GTC-3') in PCR. The
5' and 3' deleted constructs of the p53 promoter were gen-
erated by amplifying the desired sequence using p53/-
531/-3 cDNA as a template and specific primers (Table 1)
followed by their subcloning into pGL3 vector. The
deleted constructs were designated as p53/-233/-3, p53/-
172/-3, p53/-108/-3 and p53/-172/-89. The primers were
designed to contain sequences for SacI and XhoI
restriction enzymes (underlined) for cloning purpose. We
generated a pcDNA3.1-PTTG plasmid by subcloning the
full-length PTTG cDNA amplified from the human testis
into pCDNA3.1 (Invitrogen Life Technologies, Carlsbad,
CA) as described previously [2]. We generated pcDNA3.1-
p53  plasmid by subcloning the full length human p53
cDNA into pCDNA3.1. c-myc  dominant-negative
expression construct pBabe-cyc/max-64 was a generous
gift from Dr. Hartmut Land, University of Rochester.
Cell culture and transfection
We purchased HEK293, PC-3 and MCF-7 cell lines from
American Type Culture Collection (ATCC). All cells were
cultured under conditions recommended by the supplier.
For transient transfections we seeded the cells in six-well
tissue culture plates 24 hours prior to transfection. Cells
were transfected with appropriate plasmid DNA (1 µg/
well) using Fugene-6 as a transfection reagent (Boehringer
Mannheim) as described previously [2]. We used pRenila-
Luc (100 ng) (Promega, Madison, Wisconsin) as an inter-
nal control. After 48 hours of transfection, the cells were
harvested and assayed for luciferase and renilla luciferase
activities using dual-luciferase reporter system (Promega)
and quantified using a Zylux Femtometer FB12
luminometer.
Western blot analysis
The cells were harvested in lysis buffer (50 mM Tris-HCl,
8.3; 100 mM NaCl; 0.1% Triton X-100; 1 mM PMSF; 1 µg/
ml leupeptin; 1µg/ml pepstatin and 1µg/ml aprotinin)
and denatured in loading SDS sample buffer by heating at
95°C for 3 minutes. Fifty µg of proteins were separated by
electrophoresis on a 12% SDS-polyacrylamide gel and
transferred to Hybond nitrocellulose membrane (Amer-
Table 1: Sequence of different primers used in PCR amplification Construct
Construct Primer Sequence
p53/-233/-3 Sense 5'-ATGAGCTCGGATTACTTGCCCTTACT-3'
Antisense 5'-TACTCGAGAATCCAGGGAAGCGTGTC-3'
p53/-172/-3 Sense 5'-ATGAGCTCTTGATGGGATTGGGG TTTTC-3'
Antisense 5'-TACTCGAGAATCCAGGGAAGCGTGTC-3'
p53/-108/-3 Sense 5'-ATGAGCTCCAAAAGTCTAGAGCCACCGT-3'
Antisense 5'-TACTCGAGAATCCAGGGAAGCGTGTC-3'
p53/-172/-89 Sense 5'-ATGAGCTCTTGATGGGATTGGGGTT TTC-3'
Antisense 5'-TACTCGAGACGGTGGCTCTAGACTTT-3'
p53 cDNA Sense 5'-TAGGATCCGACACGCTTCCCTGGATT-3
Antisense 5'-TAGAATTCACACCTATTGCAAGCAAG-3'
Restriction enzymes SacI and XhoI sequences are underlined.Molecular Cancer 2004, 3:18 http://www.molecular-cancer.com/content/3/1/18
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sham Biosciences). The membranes were blocked in 5%
non-fat milk for 1 hour at room temperature, followed by
incubation in primary antibody for 1 hour. The antibod-
ies used were anti-PTTG (1:1,500 dilution) [42], anti-p53
(1:2,000 dilution, Zymed Laboratories, San Francisco,
California), anti-bax  (1:500 dilution, Sigma, St. Louis,
Missouri), and actin (1:5,000 dilution, Sigma). Tris-buff-
ered saline (TBS) supplemented with 0.1% Tween-20 was
used to dilute the antibodies and wash the membranes.
Proteins were visualized using the ECL system (Amersham
Biosciences) according to the supplier's instructions.
Site-directed mutagenesis
Site-directed mutagenesis of the putative c-myc/max bind-
ing sequence of the human p53 gene promoter carrying a
3-nucleotides change in p53/-172/-89 construct was car-
ried out using the Quick-Change site-directed
mutagenesis kit (Stratagene, La Jolla, CA) using p53/-172/
-89 construct as a template and selected primers (sense 5'-
TCCCCTCCCTTGGACTCAAGACTGGCGCTA-3' ; anti-
sense 5'-TAGCGCCAGTCT TGAGTCCAAGGGAGGGGA-
3') in PCR. Changing the sequence CATCTG in the wild-
type sequence to CTTGGA created the mutation in the c-
myc/max binding sequence. The construct was sequenced
to confirm the mutation and was designated p53/-172/-
89-∆-c-myc.
Preparation of nuclear extracts and DNA footprinting 
analysis
Nuclear extracts from HEK293 cells transfected with
pcDNA3.1 or pcDNA3.1-PTTG were prepared according
to Panek et al. [43]. Briefly the cells were collected in ice-
cold phosphate-buffered saline (PBS) and pelleted at
3,700 rpm for 10 minutes. The packed cell volume (PCV)
of the cells was measured and then the cells were
resuspended (3 volumes of PCV) in hypotonic buffer (1 M
HEPES, pH 7.9, 1 M MgCl2 and 1 M KCl) and incubated
for 10 minutes on ice. The resuspended cells were then
transferred to a glass homogenizer and homogenized. The
lysis of the cells was confirmed by Trypan blue dye exclu-
sion. After homogenization, the nuclei were sedimented
by centrifugation at 4,600 rpm for 15 minutes and then
resuspended (3 volumes of the sedimented nuclei) in low-
salt buffer (1 M HEPES, pH 7.9, 0.15 M MgCl2, 0.5 M
EDTA, 20 mM KCl and 25% glycerol) and mixed gently,
followed by addition of high-salt buffer (1 M HEPES, pH
7.9, 0.15 M MgCl2, 0.5 M EDTA, 1 M KCl and 25%
glycerol). The high-salt buffer was added drop wise to the
mixture with gentle mixing for 30 minutes. The mixture
was centrifuged at 5,000 rpm for 15 minutes. The
supernatant containing the nuclear extract was dialyzed
against 100 volumes of dialysis buffer (10 mM Tris-HCl,
pH 8.0, 100 mM KCl, 20% glycerol, 0.2 mM EDTA, 0.2
mM PMSF and 0.5 mM DTT) for 1 hour. The mixture was
centrifuged for 20 minutes at 5,000 rpm to pellet any pre-
cipitated proteins. and the supernatant containing the
nuclear extract was analyzed to determine the protein con-
tent and stored at -70°C.
The 84 base pair (-172 to -89) fragment of human p53
promoter was amplified using [γ-32P] end-labeled sense or
antisense primer (see Table 1 for primer sequences) and
the  p53/-172/-89 construct as a template in PCR as
described above. This [32P]-labeled DNA fragment was
purified on a 2% agarose gel. DNA footprinting analysis
was carried out in a 25 µL reaction volume containing 200
mM HEPES, pH 7.9, [32P]-labeled DNA fragment (40,000
cpm) and 50 ng/µl purified PTTG recombinant protein
[42]. The binding reaction was allowed to proceed for 10
minutes on ice. The reaction was terminated by addition
of 50 µL of stop solution A (10 mM MgCl2, 5 mM CaCl2
and 6.5 ng/µL of yeast transfer RNA) followed by diges-
tion of DNA with 0.2 unit of DNase I (Promega Biotech,
WI) for 1 minute at room temperature. The DNA diges-
tion reaction was terminated by addition of stop solution
B (20 mM EDTA, pH 8.0, 1.0% SDS and 0.2 M NaCl).
DNA was extracted with phenol/chloroform, and sepa-
rated by electrophoresis through 8% acrylamide/7 M urea
gels. The gel was dried and subjected to autoradiography.
Electrophoretic mobility shift assay (EMSA)
The [32P]-labeled DNA probe (84 bp) containing either
the wild-type or mutated c-myc/max binding sequence was
purified from agarose gel and used in gel shift assays.
Briefly, 4 µg of nuclear extract was incubated with the γ-
[32P] labeled probe (25,000 cpm) in EMSA buffer (50 mM
Tris-HCl, pH 7.5; 5 mM MgCl2; 250 mM NaCl; 2.5 mM
EDTA; 2.5 mM DTT and 20% glycerol) and 250 ng/ml
poly (dI-dC) in a 25 µl reaction volume for 30 minutes at
room temperature. For super shift assays, the nuclear
extract was incubated with PTTG  antiserum (1:1,500
diluted), N-terminal anti-c-myc  rabbit polyclonal anti-
body (0.5 µg, Santa Cruz Biotechnology, Santa Cruz, CA)
or C-terminal anti-c-myc monoclonal antibody (0.5 µg,
Zymed Laboratories, San Francisco, CA) for 30 minutes at
room temperature prior to the addition of labeled probe.
DNA-protein complexes were separated on 4% polyacry-
lamide gels and analyzed by autoradiography.
Double immunostaining of cells for PTTG and p53 
proteins
HEK293 cells were grown on polylysine-coated chamber
slides (Nunc International Corp., Naperville, IL), for 24
hours and then transfected with pcDNA3.1 or pcDNA3.1-
PTTG cDNA as described above. After 48 hours of trans-
fection, the cells were fixed with 4% freshly prepared para-
formaldehyde for 8 minutes and then treated with 0.1%
Nonidet P-40 for 5 minutes. Cells were treated with 5%
normal goat serum for 60 minutes to block nonspecific
binding followed by incubation with preimmune serumMolecular Cancer 2004, 3:18 http://www.molecular-cancer.com/content/3/1/18
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(1:1,500 dilution) plus p53 antibody (1:100 dilution) or
PTTG  antiserum (1:1,500 dilution) [42] plus p53 anti-
body (1:100 dilution) for 60 minutes at room tempera-
ture. After several rinses with PBS buffer, the cells were
incubated with Alexa Flour® 594 goat anti-mouse and
Alexa Flour® 488 goat anti-rabbit secondary antibodies
(1:500 dilution, Molecular Probes, Eugene, OR) for 45
minutes. Cells were rinsed with PBS and analyzed using a
fluorescent microscope (Olympus X-70).
Apoptosis assay and flow cytometric analysis
Apoptosis analysis of the cells was carried out using
TUNEL assay kit (Roche, Indianapolis, IN). HEK293 cells
were transiently transfected with pcDNA 3.1-PTTG or p53
plasmid as described above. After 48 hours of transfec-
tion, the cells were subjected to TUNEL assay following
the supplier's instructions. Briefly, the cells were washed
with PBS, air-dried and fixed in 4% paraformaldehyde pH
(7.4) for 1 hour at room temperature followed by incuba-
tion in permeabilization solution (0.1% Triton X-100,
0.1% sodium citrate) for 2 minutes on ice. The cells were
then washed twice with PBS and air-dried. Fifty µl of
TUNEL reaction mixture was added to each sample and
incubated in the dark in a humidified chamber for 60
minutes at 37°C. The cells were washed three times with
PBS and examined under Olympus X-70 fluorescence
microscope. For flow cytometric analysis cells were trans-
fected with pcDNA3.1-PTTG or pcDNA3.1-p53 cDNA for
24 hours and analyzed as described by Zhou et al, [25].
List of abbreviations
PTTG, pituitary tumor transforming gene; Myc DN, c-myc
dominant-negative expression construct; EMSA, electro-
phoretic mobility shift assay.
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